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INTRODUCTION 
Atrial fibrillation, the most frequently encountered arrhyth-
mia, is associated with thromboembolism and stroke which 
need to be prevented amongst other therapies involving 
rhythm control [1]. For that purpose, vitamin K antagonist, 
warfarin, has long been used despite its inconstant and unpre-
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Indications of non-vitamin K antagonist oral anticoagulants (NOACs), consisting of two types: 
direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitor (rivaroxaban, apixaban, 
and edoxaban), have expanded over the last few years. Accordingly, increasing number of 
patients presenting for surgery are being exposed to NOACs, despite the fact that NOACs are 
inevitably related to increased perioperative bleeding risk. This review article contains recent 
clinical evidence-based up-to-date recommendations to help set up a multidisciplinary man-
agement strategy to provide a safe perioperative milieu for patients receiving NOACs. In 
brief, despite the paucity of related clinical evidence, several key recommendations can be 
drawn based on the emerging clinical evidence, expert consensus, and predictable pharma-
cological properties of NOACs. In elective surgeries, it seems safe to perform high-bleeding 
risk surgeries 2 days after cessation of NOAC, regardless of the type of NOAC. Neuraxial an-
esthesia should be performed 3 days after cessation of NOACs. In both instances, dabiga-
tran needs to be discontinued for an additional 1 or 2 days, depending on the decrease in 
renal function. NOACs do not require a preoperative heparin bridge therapy. Emergent or ur-
gent surgeries should preferably be delayed for at least 12 h from the last NOAC intake (bet-
ter if > 24 h). If surgery cannot be delayed, consider using specific reversal agents, which 
are idarucizumab for dabigatran and andexanet alfa for rivaroxaban, apixaban, and edox-
aban. If these specific reversal agents are not available, consider using prothrombin com-
plex concentrates. 
Keywords: Anticoagulants; Blood loss, surgical; Emergency; Non-vitamin K antagonist; Re-
versal.  
dictable anticoagulation effect which requires constant dose 
adjustments and laboratory monitoring [2,3]. Non-vitamin K 
antagonist oral anticoagulants (NOACs), also called direct 
oral anticoagulants (DOACs), were developed as an alterna-
tive to warfarin in order to overcome the aforementioned 
pharmacological limitations of warfarin [4,5]. 
Based on cumulating clinical evidence stemming from large 
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multicenter randomized trials, NOACs were shown to be 
non-inferior to warfarin in preventing stroke and thrombo-
embolism with lower risk of serious bleeding events in pa-
tients with non-valvular atrial fibrillation [6–9]. Additionally, 
owing to the reliable pharmacokinetic properties of NOACs, 
they were prescribed in fixed doses without laboratory moni-
toring. This led to the incorporation of NOACs as valuable 
therapeutic options for anticoagulation in atrial fibrillation 
patients, by the American Heart Association (AHA)/Ameri-
can College of Cardiology (ACC)/Heart Rhythm Society 
(HRS) in 2014 [1]. With the emergence of newer evidences 
showing favorable clinical efficacy and safety of NOACs in 
various subsets of patients [10–12], focused update of the 
2014 guideline by the AHA/ACC/HRS in 2019 recommended 
the use of NOACs as first-line agents over warfarin in eligible 
patients with non-valvular atrial fibrillation (i.e., except those 
with moderate-to-severe mitral stenosis or a mechanical heart 
valve) [13]. A similar preference of NOACs over warfarin was 
also advocated by the European Heart Rhythm Association in 
2018 [14]. Furthermore, current indications of NOACs in-
clude treatment or prevention of deep vein thrombosis and 
pulmonary embolism, promoting its widespread use [15–17]. 
Accordingly, increasing number of patients presenting for 
surgery are exposed to NOACs, despite the fact that NOACs 
can inevitably increase risk of bleeding as other anticoagu-
lants. This review aimed to provide essential knowledge on 
NOACs, and evidence-based up-to-date recommendations 
regarding the perioperative management of NOACs. 
PHARMACOLOGICAL ASPECTS OF 
NOACS 
Unlike warfarin which affects multiple vitamin K-depen-
dent coagulation factors II, VII, IX, and X, NOACs were de-
signed to directly act on a single target factor to yield a more 
predictable anticoagulant response [18]. Currently, there are 4 
approved NOACs which can be divided in 2 types depending 
on their action mechanisms (Fig. 1): the direct thrombin in-
hibitor (dabigatran) [19], and the direct factor Xa inhibitors 
(rivaroxaban, apixaban, and edoxaban) which imped the con-
version of prothrombin to thrombin [20]. 
Compared to warfarin, the pharmacokinetic advantages of 
NOACs include a more rapid onset (time to peak: 1 to 3 h), 
shorter elimination half-life (5 to 15 h), lower predisposition 
to food and drug interaction (do not require restriction on vi-
tamin K-containing food), and a more predictable anticoagu-
lation effect (Table 1) [18,20]. These features allow fixed-dose 
administration in the absence of routine therapeutic laborato-
ry monitoring. Thus, the major studies that compared the ef-
ficacy of NOACs with warfarin did not carry out dose adjust-
ments or perform routine laboratory testing to detect the 
therapeutic level of NOACs [6–9]. 
NOACs undergo hepatic metabolism and plasma hydroly-
sis, and are substrates for the multidrug transporter P-glyco-
protein and CYP 3A4 metabolism, while edoxaban exists 
mostly in an unchanged form in plasma, being minimally 
metabolized through CYP 3A4 [18,20]. Therefore, concomi-
Table 1. Pharmacological Properties of Non-vitamin K Antagonists
Non-vitamin K antagonists Dabigatran Rivaroxaban Apixaban Edoxaban
Inhibitory target Thrombin Factor Xa Factor Xa Factor Xa
Time to peak 1–2 h 2–4 h 1–4 h 1–2 h
Half-life 12–17 h 5–9 h 8–15 h 10–14 h
Renal elimination 80% 33% 20% 50%
Dialyzable Yes No No No























Fig. 1. Comparison of action mechanisms between warfarin 
and non-vitamin K antagonists.
134 www.anesth-pain-med.org
Anesth Pain Med Vol. 15 No. 2
tant administration of drugs that strongly inhibit these path-
ways, such as dronedarone, amiodarone, and verapamil, may 
increase the active drug levels of the NOACs, except edoxaban 
[21]. NOACs are mostly excreted via the kidney, and approxi-
mately 80%, 33%, 27%, and 50% of dabigatran, rivaroxaban, 
apixaban, and edoxaban, respectively, undergo unchanged re-
nal elimination, mandating the need for regular monitoring 
of renal function [4]. 
BLEEDING RISK ASSOCIATED WITH 
NOACS AND REVERSAL AGENTS 
Although NOACs were shown to be associated with lower 
rates of intracranial and life-threatening bleeding when com-
pared with warfarin [22], all anticoagulants have the innate 
potential to increase bleeding risk. In patients with non-valvu-
lar atrial fibrillation treated with NOACs, the estimated pooled 
incidence of hemorrhagic stroke was 0.4% [22]. In contrast, 
NOACs conferred a 1.5-fold increased risk of gastrointestinal 
bleeding, which accounted for approximately 90% of the major 
extracranial bleeding, compared to warfarin [6,7,9,23], with an 
overall 3.3% incidence of major bleeding [24]. 
Unlike warfarin which can be readily reversed by vitamin K, 
prothrombin complex concentrates (PCC), or fresh frozen 
plasma (FFP), there were no available reversal agents for NO-
ACs during the major phase III clinical trials. Still, the fatality 
rate of patients on NOACs who exhibited major bleeding was 
similar or even less than that of patients on warfarin [22]. 
Nonetheless, bleeding complications happen, whether spon-
taneous in nature or associated with an invasive procedure/ 
surgery. Accordingly, the reversal agents developed for NO-
ACs were shown to be effective in stopping major bleeding 
events [25–27]. Although there is limited clinical evidence on 
these agents due to the unexpected nature of spontaneous 
bleeding events, two reversal agents were approved by the U.S. 
Food and Drug Administration (FDA): idarucizumab for 
dabigatran reversal and andexanet alfa for rivaroxaban and 
apixaban reversal [13]. Additionally, another reversal agent, 
ciraparantag, which can theoretically reverse the anticoagula-
tion effects of all NOACs is being studied, and the results are 
being awaited [26]. 
Idarucizumab 
Idarucizumab is a humanized monoclonal antibody frag-
ment (antigen-binding fragment; Fab) which has a 350-fold 
higher binding affinity to dabigatran than thrombin [28]. 
Thus, it frees thrombin from dabigatran inhibition and im-
mediately reverses the anticoagulation effect in a dose-depen-
dent manner after intravenous administration [29]. The rec-
ommended administration protocol suggests two 2.5 g intra-
venous boluses (total of 5 g), each given in 50 ml infusion 
over 5–10 min in order to reverse 99% of the estimated dabig-
atran’s anticoagulation effect [27]. Although its elimination 
half-life is approximately 45 min, doses of 2 g or more have 
been shown to exert a complete and sustained effect over 72 h 
[29]. Yet, administration of a second dose of 5 g may be con-
sidered, if necessary. 
While relevant clinical evidence is limited, overall, idaruci-
zumab has been shown to be effective in reversing dabiga-
tran-induced major bleeding. Its efficacy has also been shown 
in patients requiring emergency surgery, and normal hemo-
stasis with its use could be confirmed by the surgeons in ap-
proximately 93% of the patients, while the incidence of 
thromboembolic events at 30 days after idarucizumab admin-
istration was 4.8% [27]. Thus, despite the paucity of related 
clinical evidence, the U.S. FDA has approved the use of idaru-
cizumab for patients receiving dabigatran who exhibit 
life-threatening bleeding or require emergent surgery as in-
corporated in the 2019 update of AHA/ACC/HRS guidelines 
(class I recommendation, level of evidence B-NR) [13]. 
Andexanet alfa 
Andexanet is an inactive variant of human recombinant 
factor Xa in which the active serine-residue is replaced by ala-
nine to eliminate its catalytic activity and to prevent the for-
mation of prothrombin complex [30]. Thus, theoretically, an-
dexanet can reverse the anticoagulant effect of all NOACs that 
are factor Xa inhibitors, except dabigatran. Andexanet’s bind-
ing affinity to factor Xa inhibitors is similar to that of the na-
tive factor Xa [26]. 
Considering the importance of a specific reversal agent, the 
U.S. FDA has recently approved (accelerated-approval path-
way) the use of andexanet alfa for reversal of rivaroxaban- or 
apixaban-induced life-threatening or uncontrolled bleeding, 
based on the limited evidence from healthy volunteers, and 
this has newly been incorporated in the 2019 update of AHA/
ACC/HRS guidelines (class IIa recommendation, level of evi-
dence B-NR) [13]. Shortly after the approval of andexanet and 
the publication of relevant focused update by the AHA/ACC/
HRS in 2019, full study results of a prospective multicenter 
trial addressing the efficacy of andexanet alfa for bleeding as-
sociated with factor Xa inhibitors (ANNEXA-4 trial) were 
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published [25]. In that study, treatment with andexanet result-
ed in immediate reduction of anti-factor Xa activity (92% re-
duction in both apixaban and rivaroxaban), yielding good he-
mostatic efficacy in 82% of the patients at 12 h, with a throm-
boembolic event rate of 10% at 30 days. 
Current dosing recommendations are intravenous bolus 
over 15–30 min, followed by 2 h of continuous infusion: 1) 
400 mg bolus, 480 mg infusion in patients who received rivar-
oxaban (last intake >  7 h) or apixaban, and 2) 800 mg bolus, 
960 mg infusion in patients who received rivaroxaban within 
7 h (or unknown timing) or edoxaban [14,25]. 
Notably, andexanet also binds to heparin-antithrombin III 
complex, reversing the actions of low molecular-weight hepa-
rin and unfractionated heparin [31].  
Ciraparantag  
Ciraparantag is a synthetic cationic molecule that was de-
veloped to reverse the anticoagulation effect of unfractionated 
or low molecular-weight heparin via non-covalent hydrogen 
linkage and charge-charge interaction [32]. Also, it directly 
binds to Xa inhibitors and thrombin inhibitors in a similar 
manner [20]. Thus, it would be able to reverse the anticoagu-
lation effect of all NOACs, irrespective of their action mecha-
nism. Available data which show its promising results in re-
versing the anticoagulation effect of all NOACs are limited to 
animal studies or healthy volunteers [33]. Currently, ci-
raparantag is not approved for clinical use. 
ELECTIVE SURGERY AND NOACS 
Approximately 10% of patients who require oral anticoagu-
lants undergo surgery or invasive procedures yearly [34,35]. For 
patients’ safety, it is unarguable that NOACs should be appropri-
ately discontinued in patients undergoing intermediate/ high 
bleeding risk procedures. So far, clinical evidence is not enough 
to support a uniform guideline, and current recommendations 
by responsible societies including the AHA, European Heart 
Rhythm Association, and the European Society of Anaesthesiol-
ogists published in 2017, 2018, and 2017, respectively, are largely 
based on limited clinical studies and expert consensus 
[14,20,36–38]. Nonetheless, NOACs’ reliable pharmacologic 
profiles would permit safe surgery and recovery by maintaining 
the balance between bleeding and thromboembolic risk. 
To provide the patients with a safe perioperative milieu, two 
major questions arise: 1) when to discontinue NOACs before 
surgery, and 2) the need for bridge-anticoagulation therapy. 
First, NOACs have a relatively short half-life, ranging from 5 
to 15 h in patients with normal renal function [20]. Thus, dis-
continuing NOACs for 2 days before surgery with high bleed-
ing risk would allow negligible residual drug concentration 
(usually <  10% corresponding to discontinuation for 3 to 4 
half-lives), whereas discontinuation for 1 day would suffice 
for surgeries or procedures with low bleeding risk (15 to 25% 
residual activity) [38]. Notably, the elimination of NOACs de-
pends on the renal function to various degrees which must be 
assessed and properly taken into consideration before surgery. 
Based on creatinine clearance (CrCl), dabigatran needs to be 
discontinued for 3 days and 4 days with CrCl of 50 to 79 ml/
min and 30 to 49 ml/min, respectively [14]. In case of rivarox-
aban, apixaban, and edoxaban, 2 days would suffice in most 
of the patients, regardless of the renal function. In all patients, 
further consideration should be given when receiving con-
comitant dronedarone, amiodarone, or verapamil, such as 
discontinuation for an additional 1 day when the thrombo-
embolic risk is not high [14,21]. 
Second, preoperative bridge therapy with heparin is usually 
recommended for patients at high-risk of thromboembolic 
complication, such as those with mechanical heart valve [13]. 
However, as NOACs are currently not indicated in patients 
with mechanical heart valve, this recommendation does not 
apply to patients receiving NOACs. Also, the short elimination 
half-lives of NOACs require a short duration of cessation be-
fore surgery as opposed to the 5 days required in warfarin 
[20,39]. Moreover, discontinuation of NOACs has not been 
shown to result in rebound hypercoagulability [7–9]. Indeed, 
sub-analysis of major NOAC trials showed a low incidence of 
thromboembolic events ranging from 0.2 to 0.6% without 
bridging, whereas bridging with heparin resulted in increased 
bleeding complications without any benefit in terms of throm-
boembolic risk [24,40,41]. Thus, bridging therapy for NOACs 
in the preoperative period is currently not recommended, but 
it should be restarted after surgery as soon as possible [14]. 
So far, clinical evidence adhering to the above-mentioned 
recommendations for interruption of NOACs before surgery 
resulted in a similar rate of postoperative bleeding events 
when compared to patients receiving warfarin [38]. Data from 
pivotal NOACs studies including the German and Canadian 
registry, reported major bleeding incidences ranging from 0.6 
to 3% after surgery [24,42]. Recently, full data from the 
perioperative anticoagulation use for surgery evaluation 
(PAUSE) cohort trial was published, and so far, it is the largest 
prospective multicenter trial that provided more insights re-
garding the perioperative NOACs management [43]. In that 
136 www.anesth-pain-med.org
Anesth Pain Med Vol. 15 No. 2
study, NOACs were discontinued for 1 day and 2 days for 
low- and high-bleeding risk procedures, respectively. In pa-
tients receiving dabigatran, longer interruption was applied 
accounting for CrCl. NOACs were resumed 1 day and 2 to 3 
days after low- and high-bleeding risk surgeries, respectively. 
Overall, major bleeding rates were less than 2%, and the rates 
of thromboembolism were less than 1%, showing similar effi-
cacies as with warfarin and confirming the clinical usefulness 
of the simple management strategy. 
Neuraxial anesthesia, such as spinal or epidural, is consid-
ered a high-bleeding risk procedure. The most recent recom-
mendations by the American Society of Regional Anesthesia 
and Pain Medicine published in 2018 approaches NOACs on 
a more conservative basis considering the even more limited 
clinical evidence in that regard [44]. Dabigatran was recom-
mended to be discontinued for 3, 4, and 5 days in patients 
with CrCl of >  80, 50 to 79, and <  50 ml/min, respectively. 
Rivaroxaban, apixaban, and edoxaban were recommended to 
be discontinued for 3 days before Neuraxial anesthesia. 
A summary of the current recommendations incorporating 
the most recent clinical evidences are displayed in Fig. 2. 
EMERGENT/URGENT SURGERY AND 
NOACS 
In an emergent situation, NOACs should be immediately 
stopped, and the following detailed knowledge should be ac-
quired: 1) type of NOAC used, 2) last time of intake, 3) renal 
function, and 4) full panel of coagulation tests (prothrombin 
time [PT], activated partial thromboplastin time [aPTT], and 
possibly chromogenic anti-factor Xa assay, or diluted throm-
bin time [dTT]/ecarin-based assays [ECA]) [14]. 
In life-threatening or salvage emergencies such as cardiac, 
vascular, or neurosurgical surgeries that cannot be delayed 
even for a few hours, consideration should be given to admin-
ister specific reversal agents: idarucizumab for dabigatran and 
andexanet for rivaroxaban, apixaban, and edoxaban [14]. Yet, 
in case of surgeries requiring systemic heparinization, such as 
Duration of non-vitamin K antagonists interruption
Additional considerations
Consider adding an extra 24 h in patients taking dronedarone, amiodarone, or verapamil
No preoperative bridge theray with heparin is indicated during the interruption of non-vitamin K antagonists
Dabigatran is usually not indicated in patients with creatinine clearance < 30 ml/min
However, patients on dabigatran may present at the time of surgery with creatinine clearance < 30 ml/min and may require
longer than 4 days of interruption, while related evidence ensuring the safety of this protocal is lacking
Neuraxial anesthesia is not advised at creatinine clearance < 30 ml/min regardless of the type of non-vitamin K antagonist
Dabigatran Rivaroxban, apixban, edoxaban













 ≥ 72 h  ≥ 72 h ≥ 24 h  ≥ 24 h ≥ 48 h  ≥ 48 h
 ≥ 96 h  ≥ 72 h ≥ 36 h  ≥ 24 h ≥ 72 h  ≥ 48 h
 ≥ 120 h  ≥ 72 h ≥ 48 h  ≥ 24 h ≥ 96 h  ≥ 48 h
Not enough evidence Not advised Not advised ≥ 36 h  ≥ 48 h
Fig. 2. Perioperative management of non-vitamin K antagonists for elective surgery.
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cardiac or vascular, the use of andexanet may be deferred un-
til heparin reversal with protamine, as it may inhibit the anti-
coagulant effect of heparin [31] which is an absolute necessity 
for surgery. It should be noted that the incidence of thrombo-
embolic events showed a dramatic increase to 18% after ad-
ministration of the reversal agents [45,46], whereas it was less 
than 1% in case of planned interruption of NOACs [43]. 
Thus, apart from their high cost, the use of specific reversal 
agents should be carefully decided. 
If these specific reversal agents are not accessible, PCC may 
be given, although the supporting clinical evidence is limited 
and controversial [47–49]. Suggested regimens of PCC in-
clude 2 doses of 4-factor PCC or an initial bolus of 50 IU/kg 
followed by an additional 25 IU/kg if necessary [14]. FFP is 
not likely to effectively reverse NOACs, unless used in large 
volumes (at least 8–16 units of FFP would equal the dose of 
25–50 IU/kg of 4-factor PCC), and thus, it is not recommend-
ed for that purpose [50]. Also, without related clinical evi-
dence, other therapies aimed at reducing perioperative blood 
loss, such as tranexamic acid, which is an antifibrinolytic 
agent that may be considered due to its proven efficacy and 
relative safety in major surgeries [36]. 
In urgent cases that need to be done within hours, consid-
eration should be given to delaying the surgery for at least 12 
h (preferably 24 h) after the last NOAC administration, as a 
considerable amount of the given NOAC would be eliminated 
within this timespan. After delay, the coagulation tests should 
be performed again. Routine coagulation tests, such as PT 
and aPTT, cannot quantify or determine the activity of any 
given NOAC. Yet, a normal dTT or aPTT would most likely 
exclude high therapeutic levels of dabigatran, whereas normal 
PT would rule out high levels of rivaroxaban as well as edox-
aban (to a lesser extent) [51]. Despite these associations, it 
should be noted that none of the routine coagulation tests en-
sure the absence of clinically significant levels of NOACs even 
when the test results are normal [51]. Preferably, specific tests 
to measure the activity of NOACs should be performed to 
guide the need for reversal agents. These include ECA for 
dabigatran and anti-factor Xa assays for rivaroxaban, apix-
aban, or edoxaban [52–54]. However, these tests may not be 
readily available in all institutions, and clinical evidence on 
targeting therapies according to the specific test results is lack-
ing, leaving the clinical judgment at the discretion of the at-
tending physician.  
In case of dabigatran, hemodialysis may be considered, as it 
has been shown that approximately 50 to 60% of the drug was 
removed after 4 h of hemodialysis administration [55]. But, the 
practicability of hemodialysis remains questionable considering 
that it requires anticoagulation. Other NOACs are unlikely to be 
removed by hemodialysis due to their high-protein binding 
properties [56]. 
Other non-specific measures to decrease its absorption is the 
use of activated charcoal (30 to 50 g), which has been shown to 
effectively reduce the absorption of recently overdosed NOACs 
[36]. Thus, it may be considered in patients who ingested NOAC 
within 2 to 4 h before urgent surgery. However, its efficacy in pa-
tients who received a prescribed dose of NOAC, and not acci-
dental overdosed, remains questionable considering the side ef-
fects of charcoal including nausea/vomiting and aspiration [57]. 
A summary of the current recommendations incorporating 
the most recent clinical evidences are displayed in Table 2 and 
Fig. 3. 
Table 2. Reversal Agents and Alternative Options for Patients on Non-vitamin K Antagonist Requiring Emergent/Urgent Surgery
Non-vitamin K antagonists Dabigatran Rivaroxaban, apixaban, edoxaban
Reversal agents Idarucizumab Andexanet alfa
 Mode of action Humanized monoclonal antibody fragment Inactive variant of human recombinant factor Xa
 Binds to dabigatran with 350-fold higher affinity than 
thrombin
Binds to factor Xa inhibitors with similar affinity to native 
factor Xa
 Also binds to heparin-antithrombin III complex
 Dosage IV bolus of 5 g (2.5 g over 5–10 min ×  2) IV bolus over 15–30 min + 2 h of continuous infusion:
 1) 400 mg bolus, 480 mg infusion (rivaroxaban intake >  7 h 
or apixaban)
 2) 800 mg bolus, 960 mg infusion (rivaroxaban intake within 
7 h [or unknown] or edoxaban)
Alternative options Hemodialysis for 4 h Hemodialysis not applicable
PCC, 2 doses of 4-factor PCC or bolus of 50 IU/kg (+ 25 IU/kg as necessary)
Tranexamic acid, bolus 10–30 mg/kg (10–20 min) + continuous infusion 3–5 mg/kg/h
IV: intravenous, PCC: prothrombin complex concentrates.
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CONCLUSIONS 
Emerging evidence advocates the use of NOACs over warfa-
rin in patients with non-valvular atrial fibrillation, with indica-
tions expanding to patients at increased risk of deep vein 
thrombosis or pulmonary embolism [13,14,16,58]. As the field 
of anesthesiology has expanded to perioperative medicine, 
critical care, and pain medicine, patients receiving NOACs will 
be encountered more frequently in our daily practice. Practice 
guidelines regarding the management of NOACs should be 
available in every institution incorporating the recent evidence 
regarding the interruption strategy and specific reversal agents 
to provide optimal care in patients requiring surgeries. 
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Emergency (requires immediate surgery)
Consider using specific reversal agents:
1) Idarucizumab for dabigatran
2) Andexanet for rivaroxaban, apixaban, or edoxban
Consider using prothrombin complex concentrates, 
if specfic reversal agents are not available
Consider using prothrombin complex concentrates, 
if specfic reversal agents are not available
Repeat administration of specific reversal agents or
prothrombin complex concentrates, if necessary
Urgency (requires surgery within hours)
Delay surgery for > 12 h from the last non-vitamin K
antagonist (preferably > 24 h)
Repeat full coagulation tests
Consider using specific reversal agents:
1) Idarucizumab for dabigatran
2) Andexanet for rivaroxaban, apixaban, or edoxban
Consider using prothrombin complex concentrates,
if specific reversal agents are not available
Repeat administration of specific reversal agents or
prothrombin complex concentrates, if necessary
Full coagulation tests
(PT, aPTT, and possibly dTT and/or ECT for dabigatran and anti-factor Xa assay for rivaroxaban, apixban, or edoxaban)
Additional considerations
A normal aPTT or dTT may rule out high levels of dabigatran
A normal PT may rule out high levels of revaroxaban, apixban, edoxaban
None of routine coagulation tests can ensure the absence of clinically signficant levels of non-vitamin K antagonists
Risk of thromboembolic events may rise considerably after using specific reversal agents
In case of cardiac or vascular surgeries requiring systemic heparinization, use of andexanet should be dalayed until after 
the reversal of heparin as it may interfere with necessary action heparin-antithrombin III complex
Fig. 3. Perioperative management of non-vitamin K antagonists for emergent/urgent surgery. PT: prothrombin time, aPTT: activated 
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